Siemens Healthineers AG Unsponsored ADR (SMMNY)
OTHER OTC:SMMNY
Top Page
Siemens Healthineers AG Unsponsored ADR
(OTC:SMMNY)
Select Model
Select Model
Rating:56Neutral
Price Target:
$21.50
▼(-17.37% Downside)
Action:ReiteratedDate:02/08/26
The score is weighed down primarily by weak technicals (below major moving averages with negative MACD) and soft fundamental momentum (flat-to-down revenue signals and weaker/volatile free cash flow). These are partially offset by stable profitability/ROE and an earnings call that reaffirmed full-year outlook and showed strength in Imaging/Precision Therapy, though tempered by Diagnostics/China and tariff/FX headwinds.
Positive Factors
Recurring revenue from installed base
The business model emphasizes recurring revenue from services, consumables and software tied to a large installed base and long equipment replacement cycles. This creates durable revenue visibility, higher lifetime customer value and resilience versus single-sale cycles over the next 2–6 months.
Negative Factors
Diagnostics China disruption
Structural changes in China (volume‑based procurement and reimbursement cuts) are reducing prices, volumes and profit conversion for Diagnostics. Given China’s size, this creates a multi‑quarter headwind to diagnostic sales and margins until pricing/reimbursement dynamics normalize or portfolio mix shifts.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue from installed base
The business model emphasizes recurring revenue from services, consumables and software tied to a large installed base and long equipment replacement cycles. This creates durable revenue visibility, higher lifetime customer value and resilience versus single-sale cycles over the next 2–6 months.
Read all positive factors
Siemens Healthineers AG Unsponsored ADR (SMMNY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$46.22B
Dividend Yield1.98%
Average Volume (3M)1.52K
Price to Earnings (P/E)28.0
Beta (1Y)1.07
Revenue Growth6.68%
EPS Growth12.49%
CountryUS
Employees72,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.29
Shares Outstanding2,256,000,000
10 Day Avg. Volume0
30 Day Avg. Volume1,521
Financial Highlights & Ratios
PEG Ratio7.41
Price to Book (P/B)2.44
Price to Sales (P/S)2.34
P/FCF Ratio24.19
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit5.67
Enterprise Value/Ebitda11.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.35
Revenue Forecast (FY)$27.99B
Siemens Healthineers AG Unsponsored ADR Business Overview & Revenue Model
Company Description
Siemens Healthineers AG Unsponsored ADR (SMMNY) is a global leader in medical technology and healthcare solutions, providing innovative and high-quality products and services in the fields of imaging, diagnostics, and digital health. The company o...
How the Company Makes Money
Siemens Healthineers makes money primarily by selling medical equipment and related solutions, and by generating recurring revenue from services and consumables tied to its installed base. Major revenue streams include: (1) Equipment and solution ...
Siemens Healthineers AG Unsponsored ADR Earnings Call Summary
Earnings Call Date:Jan 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call presented a mix of strong operational performance in Imaging and Precision Therapy (solid growth, margin expansion ex-headwinds, strong Americas performance, product and partnership momentum, and a Moody's investment-grade rating) offset by significant challenges in Diagnostics driven by China-specific structural changes (VBP and reimbursement reductions), tariff and FX headwinds, and near-term guidance caution for Q2. Management emphasized that core synergies and operational improvements largely offset macro headwinds in Q1 and confirmed the full-year outlook, but Diagnostics and China pose material, near-term headwinds that may temper segment-level performance.Positive Updates
Strong start to fiscal 2026 and outlook confirmed
Company reported a good start to FY2026 and confirmed its full-year revenue growth and adjusted EPS outlook, citing strong operational performance in core businesses that offsets material headwinds.
Negative Updates
Diagnostics revenue decline and China market disruption
Diagnostics revenue declined ~3% in Q1, primarily due to material structural changes in China (volume-based procurement (VBP) and reimbursement reductions) that reduced prices, volumes and profit conversion and caused muted demand.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong start to fiscal 2026 and outlook confirmed
Company reported a good start to FY2026 and confirmed its full-year revenue growth and adjusted EPS outlook, citing strong operational performance in core businesses that offsets material headwinds.
Read all positive updates
Company Guidance
Siemens Healthineers confirmed its fiscal 2026 outlook while flagging short‑term China headwinds in Diagnostics: Q1 showed Imaging +5.7% (synergistic core ~6%), Precision Therapy +5.9%, Diagnostics -3%, and group revenue +3.8%; Americas +9% and China -5% (driven solely by Diagnostics). Key profit metrics: Imaging adjusted EBIT margin 21.6%, group adjusted EBIT margin 15% (flat YoY), and operational margin expansion excluding tariffs/FX of ~200 bps in Q1 (Imaging >100 bps ex‑special items; Precision Therapy ~400 bps operational uplift, with ~100 bps from special items). EPS: adjusted EPS was down ~3% YoY (Q1 down ~€0.02), but excluding tariffs and FX EPS rose ~17% YoY; Q1 saw an EPS headwind of ~€0.10 (FX ~ $0.04 in Q1, ~€0.15 full year; tariffs ~€0.06 in Q1, ~€0.15 full year) and an operational EPS improvement of ~€0.08, with a full‑year operational EPS uplift target of ~€0.25. For Q2 the company expects group growth below its 5–6% outlook range, Imaging to grow mid‑single digits, Precision Therapy mid‑ to high‑single digits, Diagnostics to decline further, and segment margins to be below prior‑year levels due to tariffs and FX; equipment book‑to‑bill in the synergistic core was 1.12 and Atellica grew ~20% in Q1 to ~70% of core lab sales.Siemens Healthineers AG Unsponsored ADR Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
66
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.90B | 22.03B | 22.36B | 21.68B | 21.71B | 18.00B |
| Gross Profit | 9.39B | 8.51B | 8.47B | 7.71B | 8.14B | 6.95B |
| EBITDA | 4.54B | 4.32B | 4.22B | 3.78B | 4.26B | 3.52B |
| Net Income | 2.11B | 2.02B | 1.94B | 1.51B | 2.04B | 1.73B |
Balance Sheet | ||||||
| Total Assets | 44.25B | 52.13B | 46.05B | 46.68B | 49.06B | 41.93B |
| Cash, Cash Equivalents and Short-Term Investments | 2.14B | 2.25B | 2.68B | 1.64B | 1.44B | 1.32B |
| Total Debt | 15.16B | 17.70B | 16.21B | 16.65B | 16.65B | 14.31B |
| Total Liabilities | 25.78B | 30.88B | 27.81B | 28.55B | 29.20B | 25.87B |
| Stockholders Equity | 18.42B | 21.20B | 18.20B | 18.08B | 19.84B | 16.04B |
Cash Flow | ||||||
| Free Cash Flow | 1.82B | 2.13B | 1.77B | 971.00M | 1.40B | 2.11B |
| Operating Cash Flow | 2.63B | 2.91B | 2.47B | 1.81B | 2.26B | 2.78B |
| Investing Cash Flow | -749.12M | -854.00M | -666.00M | -1.07B | -868.00M | -14.14B |
| Financing Cash Flow | -2.40B | -2.44B | -1.30B | -380.00M | -1.40B | 11.99B |
Siemens Healthineers AG Unsponsored ADR Technical Analysis
Negative
26.02
Price Trends
23.41
Negative
24.37
Negative
25.74
Negative
Market Momentum
-0.82
Negative
31.23
Neutral
51.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMMNY, the sentiment is Negative. The current price of 26.02 is above the 20-day moving average (MA) of 21.72, above the 50-day MA of 23.41, and above the 200-day MA of 25.74, indicating a bearish trend. The MACD of -0.82 indicates Negative momentum. The RSI at 31.23 is Neutral, neither overbought nor oversold. The STOCH value of 51.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SMMNY.
Siemens Healthineers AG Unsponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $93.36B | 48.91 | 12.53% | ― | 21.62% | 54.80% | |
67 Neutral | $111.22B | 28.29 | 9.54% | 2.76% | 5.34% | 13.15% | |
66 Neutral | $126.88B | 41.38 | 15.04% | 0.95% | 10.95% | -18.32% | |
64 Neutral | $25.80B | 24.78 | 8.21% | 3.30% | -0.76% | -55.03% | |
62 Neutral | $179.16B | 33.55 | 12.89% | 1.88% | 6.37% | 142.39% | |
56 Neutral | $46.22B | 27.96 | 11.65% | 1.98% | 6.68% | 12.49% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SMMNY
Siemens Healthineers AG Unsponsored ADR
20.79
-2.49
-10.69%
ABT
Abbott Laboratories
102.87
-19.69
-16.07%
BSX
Boston Scientific
62.82
-28.72
-31.37%
PHG
Koninklijke Philips
27.11
6.00
28.39%
MDT
Medtronic
86.63
6.04
7.50%
SYK
Stryker
331.54
-10.50
-3.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.